Can a new pill ease the strain of pulmonary arterial hypertension?

NCT ID NCT07761572

Not yet recruiting Disease control Sponsor: Cereno Scientific AB Source: ClinicalTrials.gov ↗

First seen Aug 12, 2026 · Last updated Aug 13, 2026 · Updated 1 time

Summary

This trial tests whether an experimental drug called CS1, taken as a daily pill, can improve blood vessel function in people with pulmonary arterial hypertension (PAH), a condition where high blood pressure in the lungs makes the heart work harder. Participants will receive CS1 or a placebo alongside their usual PAH medications. The study measures changes in lung blood pressure, walking distance, and risk scores over about a year to see if CS1 offers additional benefits.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CS1 (an experimental drug taken as a delayed-release capsule once daily)
What this could lead to: If successful, CS1 could become an add-on treatment to help manage pulmonary arterial hypertension, potentially improving blood flow and exercise capacity.
What could go wrong: This is a phase 2b trial with a moderate number of participants, so results may not confirm efficacy or safety. The drug is experimental, and potential side effects are not yet fully known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pulmonary arterial hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PULMONARY ARTERIAL HYPERTENSION

More trials for these conditions

Other studies related to the condition(s) this trial covers.